Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL

•A sequential MRD-guided addition of ibrutinib to venetoclax led to uMRD in 33 (87%) of 38 patients with relapsed/refractory CLL.•This MRD-driven strategy allowed identical depth of response to be reached in each patient with an individualized time-limited approach. [Display omitted] Undetectable measurable residual disease (uMRD) is achievable in patients with chronic lymphocytic leukemia (CLL) with the BCL2-inhibitor venetoclax alone or combined with the Bruton’s tyrosine kinase inhibitor ibrutinib. This phase 2, multicenter, MRD-driven study was designed to discontinue treatment upon reaching uMRD4 (